Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig, Paclitaxel, and Carboplatin in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2025
- Primary completion
- Aug 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volrustomig in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2025; status: recruiting.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07065630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065630.